Differential effects of immunosuppressive drugs on T-cell motility

American Journal of Transplantation

Volumn 6, Issue 12, 2006, Pages 2871-2883

  Datta, A ^a   David, R ^a   Glennie, S ^a   Scott, D ^a   Cernuda Morollon, E ^c   Lechler, R I ^a   Ridley, A J ^b   Marelli Berg, F M ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Cyclosporin; Migration; Rapamycin; T cells

Indexed keywords

CYCLOSPORIN A; EVEROLIMUS; IMMUNOSUPPRESSIVE AGENT; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B; STROMAL CELL DERIVED FACTOR 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL MIGRATION; CELL MOTILITY; CHEMOTAXIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFECT; DRUG INHIBITION; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; INFLAMMATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE;

EID: 33751191829     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2006.01553.x     Document Type: Article

References (41)

1. Luster AD, Alon R, von Andrian UH. Immune cell migration in inflammation: Present and future therapeutic targets. Nat Immunol 2005; 6: 1182-1190.
2. Hogg N, Laschinger M, Giles K, McDowall A. T-cell integrins: More than just sticking points. J Cell Sci 2003; 116: 4695-4705.
3. Ward SG. T lymphocytes on the move: Chemokines, PI 3-kinase and beyond. Trends Immunol 2006; 27: 80-87.
4. Jackson DE. The unfolding tale of PECAM-1. FEBS Lett 2003; 540: 7-14.
5. Luscinskas FW, Ma S, Nusrat A, Parkos CA, Shaw SK. The role of endothelial cell lateral junctions during leukocyte trafficking. Immunol Rev 2002; 186: 57-67.
6. Halloran PF. Immunosuppressive drugs for kidney transplantation. N Engl J Med 2004; 351: 2715-2729.
7. Allison AC. Immunosuppressive drugs: The first 50 years and a glance forward. Immunopharmacology 2000; 47: 63-83.
8. 2+, calcineurin, and NF-AT. Cell 1999; 96: 611-614.
9. Matsuda S, Shibasaki F, Takehana K, Mori H, Nishida E, Koyasu S. Two distinct action mechanisms of immunophilin-ligand complexes for the blockade of T-cell activation. EMBO Rep 2000; 1: 428-434.
10. Chen T, Guo J, Yang M et al. Cyclosporin A impairs dendritic cell migration by regulating chemokine receptor expression and inhibiting cyclooxygenase-2 expression. Blood 2004; 103: 413-421.
11. Hendey B, Klee CB, Maxfield FR. Inhibition of neutrophil chemokinesis on vitronectin by inhibitors of calcineurin. Science 1992; 258: 296-299.
12. Adams DH, Liu Q. FK506 inhibits human lymphocyte migration and the production of lymphocyte chemotactic factors in liver allograft recipients. Hepatology 1996; 23: 1476-1483.
13. Dumont FJ. Everolimus Novartis. Curr Opin Investig Drugs 2001; 9: 1220-1234.
14. Schuler W, Sedrani R, Cottens S et al. SDZ-RAD, a new rapamycin derivative. Transplantation 1997; 64: 36-42.
15. Chen J. Novel regulatory mechanisms of mTOR signaling. Curr Top Microbiol Immunol 2004; 279: 245-257.
16. Marelli-Berg FM, Hargreaves REG, Carmichael P, Dorling A, Lombardi G, Lechler RI. Major histocompatibility complex class II-expressing endothelial cells induce allospecific nonresponsiveness in naive T cells. J Exp Med 1996; 183: 1603-1612.
17. Scott DM, Ehrmann IE, Ellis PS et al. Identification of a mouse male-specific transplantation antigen, H-Y. Nature 1995; 376: 695-698.
18. Sidhu S, Deacock SJ, Bal V, Batchelor JR, Lombardi G, Lechler RI. Human T cells cannot act as autonomous antigen-presenting cells, but induce tolerance in antigen-specific and alloreactive responder cells. J Exp Med 1992; 176: 875-880.
19. Colantonio L, Iellem A, Clissi B et al. Upregulation of integrin alpha6/beta1 and chemokine receptor CCR1 by interleukin-12 promotes the migration of human type 1 helper T cells. Blood 1999; 94: 2981-2989.
20. Cinamon G, Shinder V, Alon R. Shear forces promote lymphocyte migration across vascular endothelium bearing apical chemokines. Nat Immunol 2001; 2: 515-522.
21. Allen WE, Zicha D, Ridley AJ, Jones GE. A role for Cdc42 in macrophage chemotaxis. J Cell Biol 1998; 141: 1147-1157.
22. James MJ, Belaramani L, Prodromidou K et al. Anergic T cells exert antigen-independent inhibition of cell-cell interactions via chemokine metabolism. Blood 2003; 102: 2173-2179.
23. Wilasrusmee C, Da Silva M, Singh B et al. Morphological and biochemical effects of immunosuppressive drugs in a capillary tube assay for endothelial dysfunction. Clin Transplant 2003; 17: 6-12.
24. Dustin ML, Cooper JA. The immunological synapse and the actin cytoskeleton: Molecular hardware for T cell signaling. Nat Immunol 2000; 1: 23-29.
25. Gajewski TF, Fields P, Fitch FW. Induction of the increased Fyn kinase activity in anergic T helper type 1 clones requires calcium and protein synthesis and is sensitive to cyclosporin A. Eur J Immunol 1995; 25: 1836-1842.
26. Popik W, Hesselgesser JE, Pitha PM. Binding of human immunodeficiency virus type 1 to CD4 and CXCR4 receptors differentially regulates expression of inflammatory genes and activates the MEK/ERK signaling pathway. J Virol 1998; 72: 6406-6413.
27. Bonacchi A, Romagnani P, Romanelli RG et al. Signal transduction by the chemokine receptor CXCR3: Activation of Ras/ERK, Src, and phosphatidylinositol 3-kinase/Akt controls cell migration and proliferation in human vascular pericytes. J Biol Chem 2001; 276: 9945-9954.
28. Jimenez-Sainz MC, Fast B, Mayor FJ, Aragay AM. Signaling pathways for monocyte chemoattractant protein 1-mediated extracellular signal-regulated kinase activation. Mol Pharmacol 2003; 64: 773-782.
29. Alahari SK, Reddig PJ, Juliano RL. Biological aspects of signal transduction by cell adhesion receptors. Int Rev Cytol 2002; 220: 145-184.
30. Ali H, Ahamed J, Hernandez-Munain C et al. Chemokine production by G protein-coupled receptor activation in a human mast cell line: Roles of extracellular signal-regulated kinase and NFAT. J Immunol 2000; 165: 7215-7223.
31. Panwalkar A, Verstovsek S, Giles FJ. Mammalian target of rapamycin inhibition as therapy for hematologic malignancies. Cancer 2004; 100: 657-666.
32. Pakala R, Stabile E, Jang GJ, Clavijo L, Waksman R. Rapamycin attenuates atherosclerotic plaque progression in apolipoprotein E knockout mice: Inhibitory effect on monocyte chemotaxis. J Cardiovasc Pharmacol 2005; 46: 481-486.
33. Tanski WJ, Nicholl SM, Kim D, Fegley AJ, Roztocil E, Davies MG. Sphingosine-1-phosphate-induced smooth muscle cell migration involves the mammalian target of rapamycin. J Vasc Surg 2005; 41: 91-98.
34. Rhoads JM, Niu X, Odle J, Graves LM. Role of mTOR signaling in intestinal cell migration. Am J Physiol Gastrointest Liver Physiol 2006; 219: G510-517.
35. Guertin DA, Sabatini DM. An expanding role for mTOR in cancer. Trends Mol Med 2005; 11: 353-361.
36. Sarbassov dos D, Ali SM, Sengupta S et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 2006; 22: 159-168.
37. Mirenda V, Lechler RI, Scott D et al. Tolerant T cells display impaired trafficking ability. Eur J Immunol 2005; 35: 2146-2156.
38. Savinov AY, Wong FS, Stonebraker AC, Chervonsky AV. Presentation of antigen by endothelial cells and chemoattraction are required for homing of insulin-specific CD8+ T cells. J Exp Med 2003; 197: 643-656.
39. Rafiee P, Johnson CP, Li MS et al. Cyclosporine A enhances leukocyte binding by human intestinal microvascular endothelial cells through inhibition of p38 MAPK and iNOS. Paradoxical proinflammatory effect on the microvascular endothelium. J Biol Chem 2002; 277: 35605-33615.
40. Mazanet MM, Neote K, Hughes CC. Expression of IFN-inducible T cell alpha chemoattractant by human endothelial cells is cyclosporin A-resistant and promotes T cell adhesion: Implications for cyclosporin A-resistant immune inflammation. J Immunol 2000; 164: 5383-5388.
41. Marelli-Berg FM, Lechler RI. Antigen presentation by parenchymal cells: A route to peripheral tolerance? Immunol Rev 1999; 172: 297-314.